Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Precipio Inc PRPO

Healthcare
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through... see more

Recent & Breaking News (NDAQ:PRPO)

Precipio Ships First IV-Cell® Order to Major US Healthcare System

GlobeNewswire March 21, 2023

CORRECTION -- Precipio continues to sign up and onboard HemeScreen(TM) customers

GlobeNewswire March 7, 2023

Precipio continues to sign up and onboard HemeScreen(TM) customers

GlobeNewswire March 7, 2023

ThermoFisher Salesforce Votes Precipio's HemeScreen® as "Best New Product"

GlobeNewswire February 14, 2023

Precipio Signs Another Major HemeScreen(TM) Customer

GlobeNewswire January 11, 2023

Precipio Signs Additional Major HemeScreen(TM) Customer

GlobeNewswire December 6, 2022

Precipio Presents Poster on HemeScreen® Study at Association of Molecular Pathology (AMP) 2022 Annual Conference

GlobeNewswire November 7, 2022

Precipio Announces Third Quarter Shareholder Update Call

GlobeNewswire November 2, 2022

Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen(TM)

GlobeNewswire September 15, 2022

Sharon Robins Joins Precipio's Products Division as Senior Director of Laboratory & Hospital Sales

GlobeNewswire August 24, 2022

Precipio Launches New 1-Step Technology for all HemeScreen Assays

GlobeNewswire August 16, 2022

Toni-Ann Mills Joins Precipio's Products Division to Lead Channel Partner Training, Learning & Development

GlobeNewswire August 10, 2022

Precipio Announces Second Quarter Shareholder Update Call

GlobeNewswire August 8, 2022

Precipio to distribute HemeScreen® through Fisher Healthcare channel

GlobeNewswire July 20, 2022

Precipio requests that all Stockholders that have not yet voted, proceed to cast their vote

GlobeNewswire June 14, 2022

Keith Meadors Joins Precipio to Lead its Products Division

GlobeNewswire June 13, 2022

Precipio Receives CE-IVD Certification to Market Multiple HemeScreen® Panels in Europe

GlobeNewswire May 24, 2022

Precipio Signs First IV-Cell Customer Agreement

GlobeNewswire May 10, 2022

Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference

GlobeNewswire April 26, 2022

Precipio Announces 2021 Fourth Quarter and Year-End Shareholder Update Call

GlobeNewswire March 22, 2022